What is B. Riley’s Forecast for AVBP Q1 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – B. Riley issued their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a report released on Wednesday, March 19th. B. Riley analyst K. Patel forecasts that the company will earn ($0.70) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $0.40 EPS.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.18.

Several other research firms have also recently issued reports on AVBP. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of ArriVent BioPharma in a research report on Friday, March 7th. Guggenheim started coverage on shares of ArriVent BioPharma in a research report on Monday, March 10th. They set a “buy” rating and a $45.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ArriVent BioPharma presently has a consensus rating of “Buy” and a consensus target price of $39.00.

ArriVent BioPharma Stock Down 0.1 %

NASDAQ AVBP opened at $19.52 on Monday. The stock has a market capitalization of $663.99 million, a P/E ratio of -7.60 and a beta of 1.00. ArriVent BioPharma has a 52-week low of $14.35 and a 52-week high of $36.37. The firm has a 50-day moving average price of $24.92 and a 200 day moving average price of $26.73.

Institutional Trading of ArriVent BioPharma

A number of institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its stake in shares of ArriVent BioPharma by 153.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock worth $4,756,000 after buying an additional 122,641 shares during the last quarter. Geode Capital Management LLC raised its position in ArriVent BioPharma by 154.2% during the third quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock worth $14,036,000 after acquiring an additional 362,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of ArriVent BioPharma in the fourth quarter valued at about $31,000. Barclays PLC grew its position in shares of ArriVent BioPharma by 1,124.8% in the third quarter. Barclays PLC now owns 41,522 shares of the company’s stock valued at $976,000 after purchasing an additional 38,132 shares during the last quarter. Finally, State Street Corp increased its stake in shares of ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company’s stock worth $11,205,000 after purchasing an additional 323,186 shares in the last quarter. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.